These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35257581)

  • 1. Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders.
    Mastromarino M; Favia M; Schepetkin IA; Kirpotina LN; Trojan E; Niso M; Carrieri A; Leśkiewicz M; Regulska M; Darida M; Rossignolo F; Fontana S; Quinn MT; Basta-Kaim A; Leopoldo M; Lacivita E
    J Med Chem; 2022 Mar; 65(6):5004-5028. PubMed ID: 35257581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.
    Stama ML; Ślusarczyk J; Lacivita E; Kirpotina LN; Schepetkin IA; Chamera K; Riganti C; Perrone R; Quinn MT; Basta-Kaim A; Leopoldo M
    Eur J Med Chem; 2017 Dec; 141():703-720. PubMed ID: 29102463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.
    Stama ML; Lacivita E; Kirpotina LN; Niso M; Perrone R; Schepetkin IA; Quinn MT; Leopoldo M
    ChemMedChem; 2017 Nov; 12(22):1839-1847. PubMed ID: 28922577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-Dependent Protective and Pro-Resolving Effects of FPR2 Agonists on Lipopolysaccharide-Exposed Microglia Cells Involve Inhibition of NF-κB and MAPKs Pathways.
    Tylek K; Trojan E; Leśkiewicz M; Regulska M; Bryniarska N; Curzytek K; Lacivita E; Leopoldo M; Basta-Kaim A
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglia Depletion Attenuates the Pro-Resolving Activity of the Formyl Peptide Receptor 2 Agonist AMS21 Related to Inhibition of Inflammasome NLRP3 Signalling Pathway: A Study of Organotypic Hippocampal Cultures.
    Tylek K; Trojan E; Leśkiewicz M; Ghafir El Idrissi I; Lacivita E; Leopoldo M; Basta-Kaim A
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Exhibits Anti-Inflammatory Activity in LPS-Stimulated Organotypic Hippocampal Cultures.
    Trojan E; Tylek K; Leśkiewicz M; Lasoń W; Brandenburg LO; Leopoldo M; Lacivita E; Basta-Kaim A
    Cells; 2021 Jun; 10(6):. PubMed ID: 34204273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
    Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functions of resolvin D1-ALX/FPR2 receptor interaction in the hemoglobin-induced microglial inflammatory response and neuronal injury.
    Liu GJ; Tao T; Wang H; Zhou Y; Gao X; Gao YY; Hang CH; Li W
    J Neuroinflammation; 2020 Aug; 17(1):239. PubMed ID: 32795323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation.
    Maciuszek M; Ortega-Gomez A; Maas SL; Perretti M; Merritt A; Soehnlein O; Chapman TM
    Eur J Med Chem; 2021 Mar; 214():113194. PubMed ID: 33548634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
    Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
    Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Lipidated Peptidomimetic Lau-((S)-Aoc)-(Lys-βNphe)6-NH2 Is a Novel Formyl Peptide Receptor 2 Agonist That Activates Both Human and Mouse Neutrophil NADPH Oxidase.
    Holdfeldt A; Skovbakke SL; Winther M; Gabl M; Nielsen C; Perez-Gassol I; Larsen CJ; Wang JM; Karlsson A; Dahlgren C; Forsman H; Franzyk H
    J Biol Chem; 2016 Sep; 291(38):19888-99. PubMed ID: 27422818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells.
    Cui YH; Le Y; Gong W; Proost P; Van Damme J; Murphy WJ; Wang JM
    J Immunol; 2002 Jan; 168(1):434-42. PubMed ID: 11751990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure.
    Asahina Y; Wurtz NR; Arakawa K; Carson N; Fujii K; Fukuchi K; Garcia R; Hsu MY; Ishiyama J; Ito B; Kick E; Lupisella J; Matsushima S; Ohata K; Ostrowski J; Saito Y; Tsuda K; Villarreal F; Yamada H; Yamaoka T; Wexler R; Gordon D; Kohno Y
    J Med Chem; 2020 Sep; 63(17):9003-9019. PubMed ID: 32407089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
    Lacivita E; Schepetkin IA; Stama ML; Kirpotina LN; Colabufo NA; Perrone R; Khlebnikov AI; Quinn MT; Leopoldo M
    Bioorg Med Chem; 2015 Jul; 23(14):3913-24. PubMed ID: 25549897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
    Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
    Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling.
    Zhang S; Gong H; Ge Y; Ye RD
    Pharmacol Res; 2020 Nov; 161():105117. PubMed ID: 32768626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology.
    Tylek K; Trojan E; Regulska M; Lacivita E; Leopoldo M; Basta-Kaim A
    Pharmacol Rep; 2021 Aug; 73(4):1004-1019. PubMed ID: 34105114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-peptide ligand binding to the formyl peptide receptor FPR2--A comparison to peptide ligand binding modes.
    Stepniewski TM; Filipek S
    Bioorg Med Chem; 2015 Jul; 23(14):4072-81. PubMed ID: 25882522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949.
    Lind S; Sundqvist M; Holmdahl R; Dahlgren C; Forsman H; Olofsson P
    Biochem Pharmacol; 2019 Aug; 166():163-173. PubMed ID: 31085160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways.
    Bozinovski S; Anthony D; Anderson GP; Irving LB; Levy BD; Vlahos R
    Pharmacol Ther; 2013 Dec; 140(3):280-9. PubMed ID: 23880288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.